Skip to main content
MyDeficiencies

Topiramate

sulfamate-substituted monosaccharide, carbonic anhydrase inhibitor

Also sold as Topamax, Trokendi XR, Qudexy XR.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Topiramate has a real, well-documented, labeled depletion and disturbance mechanism, but it is not the classic hepatic-enzyme-induction pathway that drives folate and vitamin D loss with older anticonvulsants like phenytoin, carbamazepine, and phenobarbital. Topiramate's defining mechanism is direct: the drug itself is a carbonic anhydrase inhibitor, and that inhibition causes dose-dependent renal bicarbonate wasting (hyperchloremic, non-anion-gap metabolic acidosis) in a majority of pediatric patients and a clinically meaningful share of adults. This is the strongest, best-sourced finding in this dossier and is graded red. The same carbonic-anhydrase mechanism also alters renal handling of calcium and citrate, which is the documented cause of topiramate's 2- to 4-fold increase in kidney-stone risk, and chronic acidosis is linked, in a one-year pediatric trial, to measurable bone-mineral-density loss and secondary changes in parathyroid hormone and bone turnover markers, graded orange and bounded to long-term or pediatric exposure.

sulfamate-substituted monosaccharide, carbonic anhydrase inhibitor · ATC N03AX11 · also sold as Topamax and Qsymia (combo) and Trokendi XR and Qudexy XR and generics · reviewed 2026-09-29. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Topiramate in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Bicarbonate / acid-base balance

Red — Severe

See study details

Topiramate causes dose-dependent renal bicarbonate wasting and hyperchloremic, non-anion-gap metabolic acidosis, affecting up to two-thirds of pediatric trial patients and a clinically meaningful minority of adults, through direct carbonic anhydrase inhibition.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Red

Limits on what this shows

  • Negative/null findings: None identified; the effect is consistent across adult and pediatric trial populations and across epilepsy and migraine indications.
  • At-risk subgroups: Renal disease, severe respiratory disorders, status epilepticus, diarrhea, ketogenic diet, or concurrent drugs that independently predispose to acidosis; children generally show a higher incidence than adults.

Regulatory status

Labeled warning with a specific monitoring recommendation. Boxed among "Warnings and Precautions," not a rare postmarketing signal.

Population evidence

FDA label pools data from adult adjunctive epilepsy trials and pediatric adjunctive/monotherapy trials, each a distinct Tier A regulatory-reviewed clinical trial population. Average bicarbonate decrease of 4 mEq/L at 400 mg/day in adults and ~6 mg/kg/day in pediatric patients; in pediatric adjunctive trials, decreased serum bicarbonate occurred in up to 67% of topiramate patients versus 10% on placebo, with markedly abnormal bicarbonate (<17 mEq/L, ≥5 mEq/L drop) in up to 11% versus <2% on placebo.

Mechanism

Named and direct: topiramate inhibits carbonic anhydrase, reducing renal bicarbonate reclamation.

Counter-evidence held on record

None found contradicting the direction or mechanism; this is one of the most internally consistent findings in the anticonvulsant literature. A confirmatory independent peer-reviewed study beyond the label was sought (PubMed, "topiramate metabolic acidosis prevalence serum bicarbonate") but the query was blocked by rate limiting during this review; see access notes. This is a real, medically significant loss, not a target for self-directed dietary bicarbonate or citrate supplementation. Correction, when needed, is a prescriber decision (dose reduction, or medically supervised alkali therapy), not a consumer supplement choice.

Citrate and calcium, renal handling

Orange — Moderate

See study details

Topiramate raises kidney-stone risk 2- to 4-fold in adults and up to 7% over one year in young pediatric patients, through carbonic-anhydrase-mediated increases in urinary pH and calcium and a marked reduction in urinary citrate.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange, bounded to long-term use

Limits on what this shows

  • Negative/null findings: Increased fluid intake is documented to lower the concentration of stone-forming solutes, meaning the effect is modifiable, not fixed.
  • At-risk subgroups: Personal or family history of nephrolithiasis; concurrent use with other carbonic anhydrase inhibitors (labeled to avoid); ketogenic diet.

Regulatory status

Labeled warning with a specific hydration recommendation.

Population evidence

Adjunctive adult epilepsy trials: 1.5% kidney-stone incidence, about 2 to 4 times the expected background rate. A one-year open-label extension study of 284 pediatric patients aged 1 to 24 months: 7% developed kidney or bladder stones. Increased urinary calcium and markedly decreased urinary citrate directly measured in topiramate-treated pediatric patients.

Mechanism

Named: carbonic anhydrase inhibitors reduce urinary citrate excretion (citrate normally inhibits calcium-stone crystallization) and raise urinary pH, favoring calcium phosphate stone formation.

Counter-evidence held on record

None found; this is a labeled, mechanistically clear, dose-related effect. It is graded orange rather than red because the underlying urinary citrate/calcium data come from the label's pediatric cohort rather than two fully independent published Tier A sources, and because the clinical stone outcome itself (versus the measured urinary markers) is a discrete, bounded event rather than a graded systemic deficit. This is a renal-handling effect of the drug, not evidence that consumers should limit dietary calcium or citrate; the labeled mitigation is increased fluid intake, and stone-history patients should be evaluated by a prescriber.

Calcium and parathyroid-bone turnover axis

Orange — Moderate

See study details

Topiramate is associated with reduced serum calcium, elevated parathyroid hormone, and elevated bone turnover markers in adults, and with clinically meaningful lumbar-spine bone-density loss in a pediatric trial, tracking with the severity of acidosis, though vitamin D itself is not consistently affected (see the separate Vitamin D entry).

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange, bounded to chronic/pediatric use

Limits on what this shows

  • Negative/null findings: Heo 2011 found no significant between-group difference in bone mineral density score itself or in vitamin D metabolites, only in calcium, PTH, and turnover markers; continued growth was observed in both arms of the pediatric BMD trial despite the density difference.
  • At-risk subgroups: Pediatric patients on long-term therapy; patients with lower baseline bicarbonate; premenopausal women were the only adult population directly studied.

Regulatory status

Labeled: "Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis, and may also result in osteomalacia...and/or osteoporosis with an increased risk for fractures."

Population evidence

Heo et al. 2011, Epilepsia: prospective, 36 premenopausal women on topiramate monotherapy versus 36 on carbamazepine, 32 on valproate, and controls; no significant between-group difference in bone mineral density itself, but topiramate patients had significantly lower serum calcium and higher parathyroid hormone and bone turnover markers (alkaline phosphatase, osteocalcin, collagen breakdown products) than comparators. Separately, a one-year pediatric monotherapy trial cited in the FDA label found statistically significant lumbar-spine and total-body-less-head bone mineral density decreases, with 21% of topiramate patients showing a clinically important BMD reduction (Z-score change ≥-0.5) versus 0% of controls, alongside increased urinary calcium excretion.

Mechanism

Named and drug-specific: chronic renal bicarbonate loss (see the Bicarbonate entry) drives compensatory bone buffering and secondary hyperparathyroidism.

Counter-evidence held on record

Heo 2011 is itself partly counter-evidence: it found no significant BMD difference between topiramate and comparator drugs, only biochemical differences, which bounds the claim below red. See the separate Vitamin D entry for a direct null finding on 25-hydroxyvitamin D specifically. This reflects a bone-mineral turnover effect of chronic acidosis, not a simple calcium-intake deficiency; self-directed high-dose calcium supplementation does not address the underlying acid-base mechanism and should be discussed with a prescriber, particularly given topiramate's own kidney-stone risk (above).

Folate and homocysteine

Orange — Moderate

See study details

A prospective, drug-specific study found a modest but statistically significant serum folate decline and homocysteine rise after six months of topiramate monotherapy, but a larger cross-sectional multi-drug cohort that included topiramate did not name it among the drugs significantly lowering folate.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange, bounded and contested

Limits on what this shows

  • Negative/null findings: Linnebank et al. 2011, Annals of Neurology: 2,730 AED-treated patients, 170 untreated epilepsy patients, and 200 controls; topiramate was one of the nine AEDs examined, but the drugs identified as significantly lowering folate were carbamazepine, gabapentin, oxcarbazepine, phenytoin, primidone, and valproate. Topiramate was not named among them in this larger cohort.
  • At-risk subgroups: Patients with pre-existing low folate intake or MTHFR variants; women of childbearing potential, given topiramate's separate labeled fetal-malformation risk, where periconceptional folate status is generally relevant to anticonvulsant-treated pregnancy planning.

Regulatory status

Not labeled.

Population evidence

Kim et al. 2013, Epilepsia: prospective, 109 newly diagnosed adult epilepsy patients on monotherapy (levetiracetam n=40, oxcarbazepine n=40, topiramate n=29), each patient's own baseline versus 6-month values. Topiramate arm: serum folate decreased from 139.1 to 132.1 ng/mL (5.0% decrease, p=0.014); homocysteine increased from 7.9 to 10.4 µmol/L (31.6% increase, p=0.001); LDL and apolipoprotein B also rose significantly. Belcastro et al. 2009, Epilepsia: cross-sectional comparison across new AEDs found topiramate-treated patients had elevated plasma homocysteine (mean 19.1 µmol/L, versus a 5 to 13 reference range), similar in magnitude to oxcarbazepine and older enzyme-inducing drugs, versus normal levels (~11.1 µmol/L) on lamotrigine or levetiracetam.

Mechanism

Proposed by the Belcastro authors as hepatic enzyme activation lowering folate and raising homocysteine, analogous to older enzyme-inducing anticonvulsants; the current FDA label does not itself confirm a specific CYP mechanism for topiramate (see PK basis).

Counter-evidence held on record

Linnebank 2011's larger sample not identifying topiramate as folate-lowering is directly recorded above; this is the reason the entry is capped at orange rather than red despite two smaller drug-specific studies showing a positive, statistically significant effect. Evidence is mixed and effect size, where positive, is modest. No specific supplemental folate dose is recommended here; a prescriber or pharmacist should evaluate need, especially in pregnancy planning.

Vitamin D

Yellow — Low

See study details

Bone-metabolism changes with topiramate coincide with shifts in 25-hydroxyvitamin D in FDA pediatric trial data, but the one study that directly compared vitamin D metabolites between topiramate-treated and comparator patients found no significant difference.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, mixed/theoretical

Limits on what this shows

  • Negative/null findings: Heo 2011's null result is the key negative finding and is the reason this is not graded orange alongside the calcium/PTH entry.
  • At-risk subgroups: None specifically established for vitamin D beyond the general bone-metabolism at-risk groups above.

Regulatory status

Label notes changes in "serum parathyroid hormone and 25-hydroxyvitamin D" and small decreases in "1,25-dihydroxyvitamin D" alongside bone turnover markers in the pediatric BMD trial, without isolating vitamin D as an independently significant, directionally clear finding.

Population evidence

Heo et al. 2011 (same cohort as the Calcium/PTH entry): "skeletal density scores, vitamin D metabolites, and calcium levels showed no significant differences between treatment groups" when topiramate was compared with carbamazepine, valproate, and controls, even though calcium, PTH, and turnover markers did differ.

Mechanism

Theoretical only for direct vitamin D depletion; the plausible pathway is indirect, through chronic acidosis and bone buffering (see Calcium/PTH entry), not through impaired vitamin D absorption, synthesis, or catabolism.

Counter-evidence held on record

Heo 2011's direct null comparison is the primary counter-evidence and is why this entry is not graded orange despite topiramate's well-documented bone effects. Do not conflate this with the calcium/PTH/bone entry above; the direct evidence for a vitamin D deficit specifically is weaker than the evidence for calcium and PTH changes. No dose is recommended.

Vitamin B12

Yellow — Low

See study details

A single published case report links topiramate to vitamin B12 deficiency; a larger 2,730-patient cohort that included topiramate in its drug panel did not name it among the drugs significantly lowering B12.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, case-level only

Limits on what this shows

  • Negative/null findings: Linnebank et al. 2011 included topiramate among nine AEDs studied across 2,730 patients but did not identify it among the drugs causing significant B12 or folate reduction (see Folate entry for the named drugs).
  • At-risk subgroups: Not established beyond the single case report.

Regulatory status

Not labeled.

Population evidence

Aguilar-Shea et al. 2009, Aten Primaria ("Topiramato y deficit de vitamina B12"): single adult case report of B12 deficiency temporally associated with topiramate use. Full case detail (dose, duration, B12 level, outcome) could not be retrieved in this review; see access notes.

Mechanism

Not established for topiramate specifically; proposed by analogy to enzyme-inducing anticonvulsants generally.

Counter-evidence held on record

The Linnebank 2011 null finding for topiramate, recorded in the Folate entry, applies here as well and is why this is graded yellow (single case report) rather than orange. One case report is not proof of a drug effect. No dose is recommended; routine B12 supplementation is not supported by this evidence base.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

Direction: reverse direction (as labelled in the source)

Topiramate directly engages mitochondrial carbonic anhydrase VA, and in animal/cell models this reduces, rather than causes, glucotoxicity-driven mitochondrial injury; a rare, speculative case-literature link to hyperammonemia-associated mitochondrial dysfunction also exists at the opposite end of severity.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, reverse-direction/protective, preclinical only

Limits on what this shows

  • Negative/null findings: No human mitochondrial-function data for topiramate were located in this review.
  • At-risk subgroups: For the rare hyperammonemia/possible mitochondrial signal: concurrent valproate use, per the FDA label.

Regulatory status

Not labeled as a mitochondrial toxicity; the label does document postmarketing hyperammonemia, with or without encephalopathy, especially in combination with valproate.

Population evidence

Shah 2015 (J Endocrinol Diabetes): cultured cerebral pericytes engineered to overexpress mitochondrial carbonic anhydrase VA, exposed to high glucose; topiramate treatment prevented the glucose-induced rise in reactive oxygen species and apoptosis. Animal/cell model, drug-specific to topiramate. Separately, StatPearls notes that rare clinical cases of topiramate-associated lactic acidosis and hyperammonemia "may be caused by mitochondrial dysfunction," described there as speculative rather than established.

Mechanism

Named for the protective signal: inhibition of mitochondrial CA VA reduces glucose-driven mitochondrial oxidative burden in this cell model. The rare adverse-direction case link has no confirmed mechanism.

Counter-evidence held on record

None found against the protective direction in the animal literature; the entry is graded yellow rather than higher because there is no human mitochondrial-function data and only one topiramate-specific preclinical model. This is a reverse-direction (protective) preclinical finding, not evidence of harm, and should not be read as a reason for or against mitochondrial-support supplementation. The rare case-level hyperammonemia signal is a distinct, serious clinical event that warrants prompt medical evaluation, not a nutrient-deficiency framing.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

Direction: reverse direction (as labelled in the source)

Across independent animal models in kidney, colon, hippocampus, and cerebral microvasculature, topiramate consistently lowers oxidative-stress markers rather than raising them; this is a preclinical antioxidant signal, not a depletion mechanism, and popular "topiramate causes oxidative damage" framing runs opposite to this literature.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, reverse-direction/protective, preclinical only

Limits on what this shows

  • Negative/null findings: Sarangi et al. 2016 (rat) found therapeutic-dose topiramate significantly impaired learning and memory while also assessing oxidative stress markers; this study complicates a purely protective narrative and should be weighed alongside the antioxidant-direction studies rather than treated as fully concordant with them.
  • At-risk subgroups: Not established in humans; all evidence is preclinical.

Regulatory status

Not labeled.

Population evidence

Multiple independent, topiramate-specific animal studies, all preclinical: Alsufyani et al. (rat, cadmium-induced kidney toxicity) reported topiramate showed "remarkable antioxidant and anti-apoptotic" effects; Varzandeh et al. 2024 (rat colitis model) reported protective effects via oxidative-stress inhibition; Motaghinejad and Motevalian 2016 and a related 2016 study (rat hippocampus) reported topiramate decreased methylphenidate-induced oxidative stress and was neuroprotective; Shah 2015 (cerebral pericytes, see Mitochondrial burden entry) reported reduced reactive oxygen species. A migraine-mechanism review (Chen et al. 2024) also describes topiramate as modulating oxidative stress and neurogenic inflammation in that context.

Mechanism

Not fully unified across models; proposed pathways include mitochondrial carbonic anhydrase inhibition (see Mitochondrial burden entry) and direct free-radical scavenging activity attributed to topiramate's sulfamate structure in some of these papers.

Counter-evidence held on record

Sarangi et al. 2016 is recorded above as a partially discordant note; no study reviewed found topiramate directly increasing oxidative stress markers as its primary reported finding. This is not a depletion signal and does not support antioxidant supplementation as a counter to topiramate. It is preclinical only; no human oxidative-stress biomarker study in topiramate-treated patients was located in this review.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

See study details

No topiramate-specific data exist for copper; a general epilepsy-population review reports low blood copper, alongside zinc and selenium, in epileptic patients treated with antiepileptic drugs as a class, without stratifying by specific drug.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, weak class-level only

Limits on what this shows

  • Negative/null findings: No topiramate-specific measurement, positive or negative, was located.
  • At-risk subgroups: Not established for topiramate specifically.

Regulatory status

Not labeled.

Population evidence

A 2013 Cellular and Molecular Neurobiology review, "Effects of Antiepileptic Drugs on Antioxidant and Oxidant Molecular Pathways: Focus on Trace Elements," reports antioxidant trace elements including copper as generally low in the blood of epileptic patients on antiepileptic drugs broadly. This is Tier C for topiramate: a class-level, epilepsy-population review, not a study confirmed to isolate topiramate-treated patients or their specific copper values.

Mechanism

Not established for topiramate; plausible confounders include epilepsy itself, diet, and other concurrently studied AEDs.

Counter-evidence held on record

No copper-lowering or copper-sparing finding specific to topiramate was located in PubMed searches using multiple phrasings ("topiramate copper," "topiramate copper ceruloplasmin"); the single relevant hit is the class-level review above. This is confounding-prone, class-level, non-drug-specific evidence and should not be read as topiramate-attributed. No dose is recommended.

  • Karaca et al. "Effects of Antiepileptic Drugs on Antioxidant and Oxidant Molecular Pathways: Focus on Trace Elements." Cell Mol Neurobiol. 2013. — Class-level review, epilepsy population broadly, not confirmed to stratify by topiramate. Tier C. PMID 23584684.Class-level; topiramate-specific data not confirmed.

Iron

Not graded — disclosed evidence gap

See study details

Iron

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition met: no Tier B or Tier C evidence of any kind was located linking topiramate to iron status, and no circulating consumer claim about topiramate and iron was found to rebut.

Channels tried

PubMed search-listing pages with the phrasings "topiramate iron" (11 results returned, all addressing topiramate and iron in unrelated separate contexts, e.g. obesity treatment, restless legs syndrome, migraine in iron-deficient children; none studying topiramate's effect on iron status) and "topiramate hemoglobin hematocrit" (clean zero-result page); "topiramate erythropoietin OR topiramate red blood cell" (three results, all discussing topiramate and erythropoietin as separate co-administered neuroprotective agents in perinatal asphyxia research, not a topiramate-caused iron or erythropoietic effect). This pass re-attempted the previously blocked angles across five additional channels: PubMed search-listing for "topiramate anemia" and "topiramate iron ferritin" were rate-limited (429) again on both retries; Europe PMC REST API was rate-limited (429) on retry; Crossref API returned clean, responsive results for "topiramate anemia iron," "topiramate iron ferritin," and "phentermine topiramate Qsymia anemia iron deficiency," all negative (no topiramate-relevant hit in any); Semantic Scholar API returned a clean, responsive negative result for "topiramate anemia ferritin" (ten results, all iron/anemia literature with no topiramate relevance) before being rate-limited on subsequent retries; OpenAlex was attempted repeatedly and rate-limited (429) on every attempt this pass. Also checked: StatPearls/NCBI Bookshelf topiramate monograph (no mention), DrugBank (no mention), Drugs.com and RxList consumer pages (no mention).

Assessment

A genuine literature gap, now corroborated across more independent channels than the original review: the core "hemoglobin hematocrit" PubMed query and two full Crossref queries and one Semantic Scholar query all returned clean, responsive, negative results rather than blocks, and the broader searches that did return results contained no topiramate-iron findings of any kind. PubMed's specific "topiramate anemia" and "topiramate iron ferritin" phrasings and the Europe PMC and OpenAlex channels remained rate-limited on this retry as well, so a future revision could try those specific angles again, but the volume of clean negative results across Crossref, Semantic Scholar, and PubMed's "hemoglobin hematocrit" query now makes a genuine absence of evidence, rather than a tooling artifact, the better-supported reading.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

Topiramate directly alters gut bacterial growth and composition in animal and in-vitro models: inhibiting the growth of more than ten bacterial strains in vitro, while in mice it shifts fecal microbiota toward higher Lactobacillus johnsonii and butyrate-producing Lachnospiraceae, changes framed by the study authors as contributing to seizure control rather than as harmful dysbiosis.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, preclinical only

Limits on what this shows

  • Negative/null findings: None identified specific to topiramate; no human gut-microbiome study in topiramate-treated patients was located.
  • At-risk subgroups: Not established in humans.

Regulatory status

Not labeled.

Population evidence

Thai et al. 2023, Frontiers in Microbiology: C57BL/6J mice treated with topiramate for 5 weeks; 16S rRNA fecal sequencing showed altered microbial composition, increased Lactobacillus johnsonii and Lachnospiraceae, higher fecal short-chain fatty acids, and an elevated cortical GABA/glutamate ratio, with co-administration of L. johnsonii enhancing topiramate's anti-seizure effect in a pentylenetetrazol-kindling model. Ilhan et al. 2022, Neurobiology of Disease: in-vitro screen of nine anti-seizure drug substances against early-life gut bacterial strains; topiramate (along with carbamazepine and lamotrigine) reduced growth of more than ten of the tested bacterial strains.

Mechanism

Two distinct, both drug-specific: direct antimicrobial/growth-inhibitory activity against certain strains (Ilhan), and a compositional shift toward specific taxa correlated with anti-seizure benefit (Thai).

Counter-evidence held on record

None identified; both available studies are animal/in-vitro and are not necessarily concordant in whether the net effect on the microbiome is adverse or beneficial, which is itself recorded as a limitation. This is preclinical evidence of a real biological effect, not a confirmed human dysbiosis risk in either direction. Probiotic use as a specific counter-measure is not supported by human data.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production

Yellow — Low

See study details

No study has directly measured ATP output or synthesis with topiramate; theoretical plausibility rests on topiramate's confirmed engagement of mitochondrial carbonic anhydrase VA and on a same-mechanism-class carbonic anhydrase inhibitor's demonstrated effect on mitochondrial respiration in the identical cell model.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, theoretical/class-adjacent only

Limits on what this shows

  • Negative/null findings: Direct searches for "topiramate ATP production," "topiramate ATP synthase," and "topiramate cellular respiration/creatine" returned no relevant results (see access notes).
  • At-risk subgroups: Not established.

Regulatory status

Not labeled.

Population evidence

Shah et al. 2013, Biochem Biophys Res Commun: high-glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes were reversed by pharmacological inhibition of mitochondrial carbonic anhydrases, using ethoxzolamide, not topiramate, as the study agent. This is Tier C for topiramate (a different carbonic anhydrase inhibitor, same pharmacologic mechanism class, this specific drug not in the cohort). It is mechanistically linked to Shah 2015 (see Mitochondrial burden entry), which used topiramate itself in the same pericyte/CA VA model but measured reactive oxygen species and apoptosis, not respiration or ATP directly.

Mechanism

Theoretical: if mitochondrial carbonic anhydrase VA modulates respiration (shown with ethoxzolamide) and topiramate is confirmed to engage the same target (shown for topiramate itself), an effect on ATP synthesis is plausible but has not been directly measured for topiramate.

Counter-evidence held on record

None found in either direction; this entry exists specifically because a real, if indirect, mechanistic chain exists, not because any study reported an ATP measurement for topiramate. This is the most indirect entry in this dossier. It should not be marketed as "topiramate affects your energy production"; it is a plausible, unconfirmed hypothesis built from two adjacent but distinct studies.

Oxygen delivery / utilization

Yellow — Low

See study details

Topiramate is a confirmed, crystallographically characterized inhibitor of erythrocyte carbonic anhydrase II, and carbonic anhydrase inhibition by the class-related drug acetazolamide is separately documented to alter erythrocyte 2,3-diphosphoglycerate, the key regulator of the oxyhemoglobin dissociation curve, but no study has directly measured hemoglobin, hematocrit, or tissue oxygen delivery in topiramate-treated subjects.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, structural/class-extrapolation only

Limits on what this shows

  • Negative/null findings: No topiramate-specific hemoglobin, hematocrit, red-cell mass, or arterial-oxygenation study was located in this review, and the FDA label lists no hematologic adverse-effect signal for topiramate.
  • At-risk subgroups: Not established for topiramate specifically.

Regulatory status

The FDA label documents topiramate as most active against carbonic anhydrase isozymes II and IV (see PK basis) but does not describe any hematologic or oxygen-delivery adverse effect.

Population evidence

Recacha, Costanzo, Maryanoff, Chattopadhyay, Biochem J 2002: X-ray crystal structure directly confirms topiramate bound to and inhibiting human carbonic anhydrase II, drug-specific structural/enzymatic characterization (Tier B). Shank, Smith-Swintosky, Maryanoff, J Enzyme Inhib Med Chem 2008: further drug-specific characterization of topiramate's carbonic anhydrase inhibition profile (Tier B). Carbonic anhydrase II is one of the two isoforms most heavily expressed in erythrocytes and is the catalytically dominant one, where it drives the CO2/bicarbonate buffering reaction classically described as the chloride shift. Class-level: Rolf and Garg, J Pharmacol Exp Ther 1975, found that acetazolamide, a different carbonic anhydrase inhibitor, measurably alters erythrocyte 2,3-diphosphoglycerate content and metabolism (Tier C, acetazolamide not topiramate in the cohort); 2,3-diphosphoglycerate is the primary intra-erythrocyte regulator of the oxyhemoglobin dissociation curve and therefore of tissue oxygen unloading. Raichle and Laux, 1980 (book chapter, Tier C, no specific drug), describes the general physiological mechanism by which erythrocyte carbonic anhydrase participates in oxygen delivery.

Mechanism

Named but indirect and unconfirmed for topiramate itself: inhibition of erythrocyte carbonic anhydrase II could plausibly shift 2,3-diphosphoglycerate or the oxyhemoglobin dissociation curve, by direct analogy to acetazolamide's documented effect on the same enzyme target, but no topiramate-specific functional or clinical measurement of 2,3-diphosphoglycerate, the dissociation curve, or tissue oxygenation has been located.

Counter-evidence held on record

None found against topiramate's confirmed carbonic anhydrase II binding; no topiramate-specific functional oxygen-delivery study was found to either confirm or contradict a real physiological effect, which is why this is capped at yellow rather than orange. Re-attempted PubMed search-listing queries ("topiramate hemoglobin hematocrit," clean zero-result page; "topiramate anemia" and "topiramate tissue oxygenation," rate-limited) found no direct clinical data either. Europe PMC and Semantic Scholar, the two channels hardest-hit by rate limiting in the original review, were retried in this pass: Europe PMC was blocked (429) on every retry; Semantic Scholar returned a clean, responsive result for a related hemoglobin/hematocrit/oxygen query with no topiramate-relevant hits, though it too was rate-limited on some other retries in this pass. The structural and class-extrapolation evidence above was found via Crossref, not via either of those two channels, and stands independent of their access status. This is a structural-biochemistry and class-extrapolation finding, not a clinical anemia, hypoxia, or oxygen-delivery effect. It should not be marketed as "topiramate affects your blood oxygen" and does not support any oxygen-support or hematologic supplement. It is distinct from, though mechanistically adjacent to, the renal carbonic-anhydrase-driven bicarbonate wasting graded red above; see the Overlap map.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Carnitine

    Where it comes from: Popular anticonvulsant-class "drug-nutrient depletion" material generalizes a well-documented valproate-specific carnitine effect to anticonvulsants broadly, including topiramate.

    Why it fails: A direct, drug-specific pediatric study (Zelnik et al. 2008, Pediatric Neurology; 91 children, 21 on topiramate) measured serum carnitine directly and found: "the mean serum carnitine levels of children treated with vigabatrin, lamotrigine, or topiramate were similar and normal. Only 4 children (treated with valproate) exhibited considerably lower serum carnitine levels." Carnitine depletion in this literature is a valproate-specific phenomenon, not a topiramate one, for the drug this study measured.

All references used above
  1. FDA prescribing information, TOPAMAX (topiramate), NDA 020505, Suppl-68 — Regulatory label. accessdata.fda.gov. Accessed 2026-09-29.
  2. DailyMed structured product labeling, TOPAMAX (Janssen Pharmaceuticals), setid 21628112-0c47-11df-95b3-498d55d89593 — Regulatory label cross-check. Accessed 2026-09-29.
  3. Heo K, Rhee Y, Lee HW, Lee SA, Shin DJ, Kim WJ, Song HK, Song K, Lee BI. "The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy." Epilepsia. 2011;52(10):1884-1889. — Prospective cohort, n=36 topiramate vs 36 carbamazepine, 32 valproate, controls. PMID 21692779.
  4. Kim DW, Lee SY, Shon YM, Kim JH. "Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy." Epilepsia. 2013. — Prospective, n=109 (levetiracetam 40, oxcarbazepine 40, topiramate 29), pre/post 6-month monotherapy. PMID 23980720.
  5. Belcastro V, Striano P, Gorgone G, Costa C, Ciampa C, Caccamo D, Pisani LR, Oteri G, Marciani MG, Aguglia U, Striano S, Ientile R, Calabresi P, Pisani F. "Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs." Epilepsia. 2009 (published 2010). — Cross-sectional comparison across new AEDs including topiramate. PMID 19780797.
  6. Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, Weller M, Elger CE. "Antiepileptic drugs interact with folate and vitamin B12 serum levels." Ann Neurol. 2011;69(2):352-359. — n=2,730 AED-treated patients (nine drugs including topiramate), 170 untreated epilepsy patients, 200 controls. Topiramate not named among the drugs significantly lowering folate or B12. PMID 21246600.
  7. Aguilar-Shea AL, Sierra Santos L, Castro Toro J, Gallardo-Mayo C. "Topiramato y deficit de vitamina B12." Aten Primaria. 2009;41(2):123-124. — Case report. Full case detail (dose, B12 level, outcome) not retrievable in this review window. PMID 19231712.
  8. Zelnik N, Isler N, Goez H, Shiffer M, David M, Shahar E. "Vigabatrin, lamotrigine, topiramate and serum carnitine levels." Pediatr Neurol. 2008;39(1):18-21. — n=91 children (21 on topiramate). Found normal serum carnitine in the topiramate, vigabatrin, and lamotrigine groups; low carnitine only in a 4-patient valproate subgroup. PMID 18555168.
  9. Coppola G, Epifanio G, Auricchio G, Federico RR, Resicato G, Pascotto A. "Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet." Brain Dev. 2006;28(6):358-365. — n=16 on topiramate or lamotrigine within a larger cohort. Cohort includes topiramate, but topiramate-specific numeric carnitine values could not be retrieved in this review window (PubMed individual-article page returned a bot-verification/empty response; full text not accessed). Not relied on for grading above. PMID 16376041.Not independently verified this review; cohort confirmed by title/metadata only.
  10. Shah GN. "Topiramate Protects Pericytes from Glucotoxicity: Role for Mitochondrial CA VA in Cerebromicrovascular Disease in Diabetes." J Endocrinol Diabetes. 2015. — Cell model, topiramate-specific, engineered pericytes overexpressing mitochondrial CA VA. PMID 26167540.
  11. Shah GN, Morofuji Y, Banks WA, Price TO. "High glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes is reversed by pharmacological inhibition of mitochondrial carbonic anhydrases." Biochem Biophys Res Commun. 2013. — Same model system as [10], but used ethoxzolamide, not topiramate. Tier C for topiramate; cited only for mechanism-class context. PMID 24076121.Topiramate not in this study's cohort; different carbonic anhydrase inhibitor used.
  12. Alsufyani HA, et al. Topiramate antioxidant/anti-apoptotic effects in cadmium-induced kidney toxicity, rat model. 2026. — Animal study, topiramate-specific. PMID 40643873.
  13. Varzandeh M, et al. Topiramate protective effect via oxidative-stress inhibition in a rat colitis model. 2024. — Animal study, topiramate-specific. PMID 37632553.
  14. Motaghinejad M, Motevalian M. Topiramate decreased methylphenidate-induced oxidative stress in rat hippocampus. 2016. — Animal study, topiramate-specific. PMID 27105819.
  15. Motaghinejad M, et al. Neuroprotective effects of topiramate against methylphenidate-induced oxidative stress in rat hippocampus. 2016. — Animal study, topiramate-specific. PMID 26718459.
  16. Sarangi SC, et al. Topiramate at therapeutic doses impaired learning/memory in a rodent seizure-kindling model. 2016. — Animal study, topiramate-specific; recorded as a partial counter-note to the oxidative-stress entry. PMID 27834333.
  17. Karaca et al. "Effects of Antiepileptic Drugs on Antioxidant and Oxidant Molecular Pathways: Focus on Trace Elements." Cell Mol Neurobiol. 2013. — Class-level review, epilepsy population broadly, not confirmed to stratify by topiramate. Tier C. PMID 23584684.Class-level; topiramate-specific data not confirmed.
  18. Thai K, Taylor MW, Fernandes T, Akinade EA, Campbell SL. "Topiramate alters the gut microbiome to aid in its anti-seizure effect." Front Microbiol. 2023. — Mouse model, topiramate-specific, 16S rRNA sequencing. PMID 37942078.
  19. Ilhan ZE, Brochard V, Lapaque N, Auvin S, Lepage P. "Exposure to anti-seizure medications impact growth of gut bacterial species and subsequent host response." Neurobiol Dis. 2022;167. — In-vitro screen of nine anti-seizure drugs including topiramate against gut bacterial strains. PMID 35183703.
  20. Recacha R, Costanzo MJ, Maryanoff BE, Chattopadhyay D. "Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate." Biochem J. 2002;361(Pt 3):437-441. — X-ray crystal structure, topiramate-specific, confirms direct binding to and inhibition of human carbonic anhydrase II. Retrieved via Crossref metadata (PubMed direct access blocked this review). DOI 10.1042/bj3610437.
  21. Shank RP, Smith-Swintosky VL, Maryanoff BE. "Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate." J Enzyme Inhib Med Chem. 2008;23(2):271-276. — Topiramate-specific carbonic anhydrase inhibition profile. Abstract text not retrievable via Crossref/OpenAlex metadata this review; citation and journal/page data confirmed. DOI 10.1080/14756360701507001.Abstract not independently verified this review; citation confirmed by title/journal metadata only.
  22. Rolf LL Jr, Garg LC. "The effect of acetazolamide and carbonic anhydrase inhibition on erythrocyte 2,3-diphosphoglycerate content and metabolism." J Pharmacol Exp Ther. 1975;193(2):639-646. — Class-level mechanism reference for oxygen delivery/utilization entry; acetazolamide, not topiramate, was the study agent. Abstract text not retrievable via Crossref/OpenAlex metadata this review. DOI 10.1016/s0022-3565(25)30181-3.Topiramate not in this study's cohort; different carbonic anhydrase inhibitor used. Cited for mechanism-class context only.
  23. Raichle ME, Laux BE. "Role of erythrocyte carbonic anhydrase in oxygen delivery to brain." In: Microsurgery for Cerebral Ischemia. 1980. — General physiology book chapter, no specific drug studied; cited for mechanism-class context only on the erythrocyte-carbonic-anhydrase-to-oxygen-delivery pathway. DOI 10.1007/978-1-4612-6090-5_1.No drug studied; general physiology reference only.
  24. StatPearls, "Topiramate," NCBI Bookshelf NBK554530. — Pharmacology reference; mechanism, monitoring, and a brief note on speculative mitochondrial dysfunction in rare hyperammonemia cases.
  25. DrugBank, Topiramate, DB00273. — Pharmacodynamics and ATC code cross-check.
  26. Drugs.com, Topiramate side effects. — Consumer circulating-claim audit; bicarbonate and bone-health content consistent with the label.
  27. RxList, Topamax drug page. — Consumer circulating-claim audit; bone/PTH/25-OH-D content consistent with the label.